Trial Profile

The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms SPRINT

Most Recent Events

03 Dec 2024 Status changed from active, no longer recruiting to completed.
12 Nov 2023 Results published in the Journal of Clinical Oncology
11 Jul 2022 Planned End Date changed from 1 Sep 2022 to 18 Nov 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com